BiotechTube

ACE-536

Phase 2Recruiting
0 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Beta-Thalassemia

Conditions

Beta-Thalassemia

Trial Timeline

Nov 7, 2019 → Jun 11, 2035

NCT ID
NCT04143724

About ACE-536

ACE-536 is a phase 2 stage product being developed by Merck for Beta-Thalassemia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04143724. Target conditions include Beta-Thalassemia.

What happened to similar drugs?

2 of 7 similar drugs in Beta-Thalassemia were approved

Approved (2) Terminated (0) Active (5)
✅DeferasiroxNovartisApproved
🔄deferasiroxNovartisPhase 3
🔄ICL670 + deferoxamineNovartisPhase 3
✅ICL670NovartisApproved
🔄CTX001Vertex PharmaceuticalsPhase 3
🔄CTX001Vertex PharmaceuticalsPhase 3
🔄CTX001Vertex PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT04143724Phase 2Recruiting
NCT01432717Phase 1Completed

Competing Products

18 competing products in Beta-Thalassemia

See all competitors
ProductCompanyStageHype Score
DeferasiroxNovartisApproved
43
Zoledronic acid + PlaceboNovartisPhase 2/3
34
deferasiroxNovartisPhase 3
40
ICL670 + deferoxamineNovartisPhase 3
40
DeferasiroxNovartisPhase 2
35
DeferasiroxNovartisPhase 2
35
ICL670NovartisApproved
43
BitopertinRochePhase 2
35
Luspatercept + PlaceboBristol Myers SquibbPhase 2
39
CTX001Vertex PharmaceuticalsPhase 3
44
CTX001Vertex PharmaceuticalsPhase 3
47
CTX001Vertex PharmaceuticalsPhase 2/3
38
CTX001Vertex PharmaceuticalsPhase 3
47
Mozobil + Mozobil + MozobilSanofiPre-clinical
26
Deferitrin (GT56-252) + desferoxamine (DFO)SanofiPhase 1/2
32
REGN7999 + PlaceboRegeneron PharmaceuticalsPhase 2
42
VIT-2763 60 mg QD + VIT-2763 60 mg BID + VIT-2763 120 mg BID + PlaceboLabCorpPhase 2
24
VIT-2763 once a day (QD) + VIT-2763 twice a day (BID) + PlaceboLabCorpPhase 2
32